Halozyme CFO Nicole LaBrosse to depart by March 30, 2026 under transition agreement

HALOZYME THERAPEUTICS, INC.

CFO Nicole LaBrosse will remain until new CFO is hired or March 30, 2026, whichever comes first.
Transition agreement provides 120% target bonus for 2025, severance equal to base salary plus pro-rated 2026 bonus.
Equity awards vesting through February 28, 2026 will accelerate; option exercise period extended to one year post-separation.
If a Change in Control occurs within one year after separation, unvested options will fully vest.
COBRA coverage premiums paid for one year; agreement filed with 2025 10-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.